Febuksostat etkileşimleri

ksantin oksidaz inhibitörü sınıfından Febuksostat (Uloric) için dizinlediğimiz FDA etiketlerinde ve bilgi sayfalarında 136 belgelenmiş etkileşim var: 10 majör, 88 orta, 28 minör ve bir etiketin anlamlı etkileşim olmadığını bildirdiği 10 çift. Aşağıdaki her kayıt, dayandığı cümleyi alıntılar. Bu ilaç sayfası bir başlangıç noktasıdır; sizin durumunuz için verilmiş bir hüküm değildir.

Etikete göre etkileşimler

Majör etkileşimler (10)

  • AdenozinantiaritmikMajör

    Use of methylxanthines (e.g., caffeine, aminophylline and theophylline) is not recommended in patients who experience a seizures in association with adenosine injection ( 5.6 ) (Adenozin etiketi, Uyarılar ve önlemler)

  • AdrenalinsempatomimetikMajör

    …hormones Diuretics Cardiac glycosides, such as digitalis glycosides Quinidine Drugs potentiating hypokalemic effects of epinephrine • Potassium depleting diuretics • Corticosteroids • Theophylline Epinephrine should not be used to counteract circulatory collapse or hypotension caused by phenothiazines, as a reversal of the pressor effects of epinephrine may result… (Adrenalin etiketi, İlaç etkileşimleri)

  • Allopurinolksantin oksidaz inhibitörüMajör

    WARNING: CARDIOVASCULAR DEATH Gout patients with established cardiovascular (CV) disease treated with ULORIC had a higher rate of CV death compared to those treated with allopurinol in a CV outcomes study [see Warnings and Precautions (5.1) ] . (Febuksostat etiketi, Kutulu uyarı)

  • AzatioprinimmünosüpresanMajör

    ULORIC is contraindicated in patients being treated with azathioprine or mercaptopurine [see Drug Interactions (7) ] . (Febuksostat etiketi, Kontrendikasyonlar)

  • Deferasiroksdemir takviyesiMajör

    Avoid the use of Exjade with CYP1A2 substrate theophylline. (Deferasiroks etiketi, İlaç etkileşimleri)

  • KetaminMSS depresanıMajör

    Theophylline or Aminophylline : Do not co-administer with KETALAR as concomitant use may lower the seizure threshold ( 7.1 ). (Ketamin etiketi, İlaç etkileşimleri)

  • MerkaptopürinantimetabolitMajör

    ULORIC is contraindicated in patients being treated with azathioprine or mercaptopurine [see Drug Interactions (7) ] . (Febuksostat etiketi, Kontrendikasyonlar)

  • RifampisinantibiyotikMajör

    Quinine Prevention or Management : Avoid concomitant use Decrease AUC by 75%-85% Telithromycin Decrease AUC by 86% Theophylline Decrease exposure by 20%-40% Effect of Other Drugs on Rifampin Concomitant antacid administration may reduce the absorption of rifampin. (Rifampisin etiketi, İlaç etkileşimleri)

  • RiosiguatvazodilatörMajör

    Phosphodiesterase Inhibitors Concomitant administration of Adempas with specific PDE-5 inhibitors (such as sildenafil, tadalafil, or vardenafil) or nonspecific PDE-5 inhibitors (such as dipyridamole or theophylline) is contraindicated [see Dosage and Administration (2.6), Drug Interactions ( 7.1 ) and Clinical Pharmacology ( 12.2 )]. (Riosiguat etiketi, Kontrendikasyonlar)

  • SiprofloksasinflorokinolonMajör

    Serious Adverse Reactions with Concomitant Theophylline Serious and fatal reactions have been reported in patients receiving concurrent administration of ciprofloxacin and theophylline. (Siprofloksasin etiketi, Uyarılar ve önlemler)

Orta düzey etkileşimler (88)

  • AdalimumabimmünosüpresanOrta

    Upon initiation or discontinuation of Adalimumab-fkjp in patients being treated with CYP450 substrates with a narrow therapeutic index, monitoring of the effect (e.g., warfarin) or drug concentration (e.g., cyclosporine or theophylline) is recommended and the individual dose of the drug product may be adjusted as needed. (Adalimumab etiketi, İlaç etkileşimleri)

  • AklidinyumantikolinerjikOrta

    Sympathomimetics, Methylxanthines, Steroids In clinical studies, concurrent administration of aclidinium bromide and other drugs commonly used in the treatment of COPD including sympathomimetics (short-acting beta 2 agonists), methylxanthines, and oral and inhaled steroids showed no increases in adverse drug reactions. (Aklidinyum etiketi, İlaç etkileşimleri)

  • Theophylline: Albendazole induces cytochrome P450 1A in human hepatoma cells; therefore, it is recommended that plasma concentrations of theophylline be monitored during and after treatment. (Albendazol etiketi, İlaç etkileşimleri)

  • Arformoterolbeta adrenerjik agonistOrta

    Xanthine derivatives, steroids, diuretics, or non-potassium sparing diuretics may potentiate hypokalemia or ECG changes. (Arformoterol etiketi, İlaç etkileşimleri)

  • AspirinNSAİİOrta

    Consider use of prophylactic low-dose aspirin therapy in patients with a history of CV disease. (Febuksostat etiketi, Uyarılar ve önlemler)

  • Aspirin ve dipiridamolantitrombosit ilaçOrta

    Consider use of prophylactic low-dose aspirin therapy in patients with a history of CV disease. (Febuksostat etiketi, Uyarılar ve önlemler)

  • BupropionantidepresanOrta

    …also increase the risk of seizure: concomitant use of other medications that lower the seizure threshold (e.g., other bupropion products, antipsychotics, tricyclic antidepressants, theophylline, and systemic corticosteroids), metabolic disorders (e.g., hypoglycemia, hyponatremia, severe hepatic impairment, and hypoxia), or use of illicit drugs (e.g., cocaine)… (Bupropion etiketi, Uyarılar ve önlemler)

  • Consider use of prophylactic low-dose aspirin therapy in patients with a history of CV disease. (Febuksostat etiketi, Uyarılar ve önlemler)

  • Consider use of prophylactic low-dose aspirin therapy in patients with a history of CV disease. (Febuksostat etiketi, Uyarılar ve önlemler)

  • ButorfanolopioidOrta

    …Interactions It is not known if the effects of Butorphanol Tartrate Injection are altered by concomitant medications that affect hepatic metabolism of drugs (CYP 450 inhibitors or inducers) (e.g., erythromycin, theophylline, etc.), but physicians should be alert to the possibility that a smaller initial dose and longer intervals between doses may be needed. (Butorfanol etiketi, İlaç etkileşimleri)

  • Desogestrel ve etinilestradioloral kontraseptifOrta

    Effects of Combined Hormonal Contraceptives on Other Drugs COCs containing EE may inhibit the metabolism of other compounds (e.g., cyclosporine, prednisolone, theophylline, tizanidine, and voriconazole) and increase their plasma concentrations. (Desogestrel ve etinilestradiol etiketi, İlaç etkileşimleri)

  • DiflunisalNSAİİOrta

    In order to prevent gout flares when ULORIC is initiated, concurrent prophylactic treatment with an NSAID or colchicine is recommended [see Dosage and Administration (2.4) ]. (Febuksostat etiketi, Uyarılar ve önlemler)

  • DiklofenakNSAİİOrta

    In order to prevent gout flares when ULORIC is initiated, concurrent prophylactic treatment with an NSAID or colchicine is recommended [see Dosage and Administration (2.4) ]. (Febuksostat etiketi, Uyarılar ve önlemler)

  • In order to prevent gout flares when ULORIC is initiated, concurrent prophylactic treatment with an NSAID or colchicine is recommended [see Dosage and Administration (2.4) ]. (Febuksostat etiketi, Uyarılar ve önlemler)

  • Diklorfenamidkarbonik anhidraz inhibitörüOrta

    Drugs that Cause Hypokalemia The risk of hypokalemia is greater with coadministration of KEVEYIS and other drugs that can cause hypokalemia (e.g., loop diuretics, thiazide diuretics, laxatives, antifungals, penicillins, and theophylline) [see Warnings and Precautions (5.3) ] . (Diklorfenamid etiketi, İlaç etkileşimleri)

  • There may be an interaction between doxapram and aminophylline and between doxapram and theophylline manifested by increased skeletal muscle activity, agitation, and hyperactivity. (Doksapram etiketi, İlaç etkileşimleri)

  • Drospirenon ve etinilestradioloral kontraseptifOrta

    …studies, administration of a hormonal contraceptive containing EE did not lead to any increase or only to a weak increase in plasma concentrations of CYP3A4 substrates (e.g., midazolam) while plasma concentrations of CYP2C19 substrates (e.g., omeprazole and voriconazole) and CYP1A2 substrates (e.g., theophylline and tizanidine) can have a weak or moderate increase. (Drospirenon ve etinilestradiol etiketi, İlaç etkileşimleri)

  • Dutasterid ve tamsulosin5-alfa redüktaz inhibitörüOrta

    Tamsulosin Dosage adjustments are not necessary when tamsulosin is administered concomitantly with digoxin or theophylline [see Clinical Pharmacology (12.3) ]. (Dutasterid ve tamsulosin etiketi, İlaç etkileşimleri)

  • Eritromisinmakrolid antibiyotikOrta

    Drug Interactions Theophylline Erythromycin use in patients who are receiving high doses of theophylline may be associated with an increase in serum theophylline levels and potential theophylline toxicity. (Eritromisin etiketi, İlaç etkileşimleri)

  • EtodolakNSAİİOrta

    In order to prevent gout flares when ULORIC is initiated, concurrent prophylactic treatment with an NSAID or colchicine is recommended [see Dosage and Administration (2.4) ]. (Febuksostat etiketi, Uyarılar ve önlemler)

  • Effects of CHCs on Other Drugs CHCs containing ethinyl estradiol may inhibit the metabolism of other compounds (e.g., cyclosporine, prednisolone, theophylline, tizanidine, and voriconazole) and increase their plasma concentrations. (Etonogestrel ve etinilestradiol etiketi, İlaç etkileşimleri)

  • FenitoinantikonvülsanOrta

    John’s wort may vary widely based on preparation. , sucralfate, theophylline Drugs that may either increase or decrease phenytoin serum levels Antiepileptic drugs Phenobarbital, valproate sodium Valproate sodium and valproic acid are similar medications. (Fenitoin etiketi, İlaç etkileşimleri)

  • FenoprofenNSAİİOrta

    In order to prevent gout flares when ULORIC is initiated, concurrent prophylactic treatment with an NSAID or colchicine is recommended [see Dosage and Administration (2.4) ]. (Febuksostat etiketi, Uyarılar ve önlemler)

  • Flukonazolazol antifungalOrta

    (See CLINICAL PHARMACOLOGY: Drug Interaction Studies .) Theophylline Fluconazole increases the serum concentrations of theophylline. (Flukonazol etiketi, İlaç etkileşimleri)

  • FlurbiprofenNSAİİOrta

    In order to prevent gout flares when ULORIC is initiated, concurrent prophylactic treatment with an NSAID or colchicine is recommended [see Dosage and Administration (2.4) ]. (Febuksostat etiketi, Uyarılar ve önlemler)

  • FluvoksaminSSRIOrta

    Theophylline: Clearance decreased; reduce theophylline dose by one-third ( 5.8 ). (Fluvoksamin etiketi, Uyarılar ve önlemler)

  • Formoterolbeta adrenerjik agonistOrta

    • Xanthine derivatives, steroids, diuretics, or non-potassium sparing diuretics may potentiate hypokalemia or ECG changes. (Formoterol etiketi, İlaç etkileşimleri)

  • FosfenitoinantikonvülsanOrta

    John's wort may vary widely based on preparation. theophylline Drugs that may either increase or decrease phenytoin serum levels Antiepileptic drugs Phenobarbital, valproate sodium, valproic acid 7.2 Drugs Affected by Phenytoin or CEREBYX Table 7 includes commonly occurring drug interactions affected by phenytoin (the active metabolite of CEREBYX). (Fosfenitoin etiketi, İlaç etkileşimleri)

  • In order to prevent gout flares when ULORIC is initiated, concurrent prophylactic treatment with an NSAID or colchicine is recommended [see Dosage and Administration (2.4) ]. (Febuksostat etiketi, Uyarılar ve önlemler)

  • İbuprofenNSAİİOrta

    In order to prevent gout flares when ULORIC is initiated, concurrent prophylactic treatment with an NSAID or colchicine is recommended [see Dosage and Administration (2.4) ]. (Febuksostat etiketi, Uyarılar ve önlemler)

  • In order to prevent gout flares when ULORIC is initiated, concurrent prophylactic treatment with an NSAID or colchicine is recommended [see Dosage and Administration (2.4) ]. (Febuksostat etiketi, Uyarılar ve önlemler)

  • İndometazinNSAİİOrta

    In order to prevent gout flares when ULORIC is initiated, concurrent prophylactic treatment with an NSAID or colchicine is recommended [see Dosage and Administration (2.4) ]. (Febuksostat etiketi, Uyarılar ve önlemler)

  • İnfliksimabimmünosüpresanOrta

    Upon initiation or discontinuation of RENFLEXIS in patients being treated with CYP450 substrates with a narrow therapeutic index, monitoring of the effect (e.g., warfarin) or drug concentration (e.g., cyclosporine or theophylline) is recommended and the individual dose of the drug product may be adjusted as needed. (İnfliksimab etiketi, İlaç etkileşimleri)

  • İzoniazidantibiyotikOrta

    Theophylline A recent study has shown that concomitant administration of isoniazid and theophylline may cause elevated plasma levels of theophylline, and in some instances a slight decrease in the elimination of isoniazid. (İzoniazid etiketi, İlaç etkileşimleri)

  • Kannabidiol (reçeteli)antikonvülsanOrta

    Increases in exposure of certain CYP1A2 substrates (e.g., theophylline, tizanidine) may be observed when concomitantly used with EPIDIOLEX. (Kannabidiol (reçeteli) etiketi, İlaç etkileşimleri)

  • KetoprofenNSAİİOrta

    In order to prevent gout flares when ULORIC is initiated, concurrent prophylactic treatment with an NSAID or colchicine is recommended [see Dosage and Administration (2.4) ]. (Febuksostat etiketi, Uyarılar ve önlemler)

  • KetorolakNSAİİOrta

    In order to prevent gout flares when ULORIC is initiated, concurrent prophylactic treatment with an NSAID or colchicine is recommended [see Dosage and Administration (2.4) ]. (Febuksostat etiketi, Uyarılar ve önlemler)

  • KininantimalaryalOrta

    Theophylline or Aminophylline In 20 healthy subjects who received multiple doses of quinine sulfate (648 mg every 8 hours x 7 days) with a single 300 mg oral dose of theophylline, the quinine mean C max and AUC were increased by 13% and 14% respectively. (Kinin etiketi, İlaç etkileşimleri)

  • Klaritromisinmakrolid antibiyotikOrta

    Xanthine Derivatives: Theophylline Use With Caution Theophylline: Clarithromycin use in patients who are receiving theophylline may be associated with an increase of serum theophylline concentrations [see Pharmacokinetics ( 12.3 )] . (Klaritromisin etiketi, İlaç etkileşimleri)

  • In order to prevent gout flares when ULORIC is initiated, concurrent prophylactic treatment with an NSAID or colchicine is recommended [see Dosage and Administration (2.4) ]. (Febuksostat etiketi, Uyarılar ve önlemler)

  • Lansoprazolproton pompası inhibitörüOrta

    Theophylline Clinical Impact: Increased clearance of theophylline [see Clinical Pharmacology (12.3) ] . (Lansoprazol etiketi, İlaç etkileşimleri)

  • LeflunomidimmünosüpresanOrta

    In patients taking ARAVA, exposure of drugs metabolized by CYP1A2 (e.g., alosetron, duloxetine, theophylline, tizanidine) may be reduced. (Leflunomid etiketi, İlaç etkileşimleri)

  • LevofloksasinflorokinolonOrta

    However, concomitant administration of other fluoroquinolones with theophylline has resulted in prolonged elimination half-life, elevated serum theophylline levels, and a subsequent increase in the risk of theophylline-related adverse reactions in the patient population. (Levofloksasin etiketi, İlaç etkileşimleri)

  • Concomitant use with ethinyl estradiol-containing CHCs may increase systemic exposure of other drugs (e.g., cyclosporine, prednisolone, theophylline, tizanidine, and voriconazole). (Levonorgestrel ve etinilestradiol etiketi, İlaç etkileşimleri)

  • LevosetirizinantihistaminikOrta

    There was a small decrease (~16%) in the clearance of cetirizine caused by a 400 mg dose of theophylline. (Levosetirizin etiketi, İlaç etkileşimleri)

  • Mefenamik asitNSAİİOrta

    In order to prevent gout flares when ULORIC is initiated, concurrent prophylactic treatment with an NSAID or colchicine is recommended [see Dosage and Administration (2.4) ]. (Febuksostat etiketi, Uyarılar ve önlemler)

  • MeksiletinantiaritmikOrta

    Concurrent use of mexiletine and theophylline may lead to increased plasma theophylline levels. (Meksiletin etiketi, İlaç etkileşimleri)

  • MeloksikamNSAİİOrta

    In order to prevent gout flares when ULORIC is initiated, concurrent prophylactic treatment with an NSAID or colchicine is recommended [see Dosage and Administration (2.4) ]. (Febuksostat etiketi, Uyarılar ve önlemler)

  • Metimazolantitiroid ilaçOrta

    Theophylline: Theophylline clearance may decrease when hyperthyroid patients on a stable theophylline regimen become euthyroid; a reduced dose of theophylline may be needed. (Metimazol etiketi, İlaç etkileşimleri)

  • MetotreksatimmünosüpresanOrta

    Effect of XATMEP on Other Drugs Theophylline Methotrexate may decrease the clearance of theophylline. (Metotreksat etiketi, İlaç etkileşimleri)

  • NabumetonNSAİİOrta

    In order to prevent gout flares when ULORIC is initiated, concurrent prophylactic treatment with an NSAID or colchicine is recommended [see Dosage and Administration (2.4) ]. (Febuksostat etiketi, Uyarılar ve önlemler)

  • Naltrekson ve bupropionopioid antagonistiOrta

    …may cause hypoglycemia concomitant administration of medications that may lower the seizure threshold, including other bupropion products, antipsychotics, tricyclic antidepressants, theophylline, systemic steroids Recommendations for Reducing the Risk of Seizure: Clinical experience with bupropion suggests that the risk of seizure may be minimized by adhering to… (Naltrekson ve bupropion etiketi, Uyarılar ve önlemler)

  • NaproksenNSAİİOrta

    In order to prevent gout flares when ULORIC is initiated, concurrent prophylactic treatment with an NSAID or colchicine is recommended [see Dosage and Administration (2.4) ]. (Febuksostat etiketi, Uyarılar ve önlemler)

  • In order to prevent gout flares when ULORIC is initiated, concurrent prophylactic treatment with an NSAID or colchicine is recommended [see Dosage and Administration (2.4) ]. (Febuksostat etiketi, Uyarılar ve önlemler)

  • NefazodonantidepresanOrta

    FEV 1 measurements taken when theophylline and nefazodone were coadministered did not differ from baseline dosage (i.e., when theophylline was administered alone). (Nefazodon etiketi, İlaç etkileşimleri)

  • Effects of Combined Hormonal Contraceptives on Other Drugs CHCs containing EE may inhibit the metabolism of other compounds (e.g., cyclosporine, prednisolone, theophylline, tizanidine, and voriconazole) and increase their plasma concentrations. (Norelgestromin ve etinilestradiol etiketi, İlaç etkileşimleri)

  • Norgestimat ve etinilestradioloral kontraseptifOrta

    Effects of Combined Oral Contraceptives on Other Drugs COCs containing EE may inhibit the metabolism of other compounds (e.g., cyclosporine, prednisolone, theophylline, tizanidine, and voriconazole) and increase their plasma concentrations. (Norgestimat ve etinilestradiol etiketi, İlaç etkileşimleri)

  • Norgestrel ve etinilestradioloral kontraseptifOrta

    Effects of Combined Oral Contraceptives on Other Drugs COCs containing EE may inhibit the metabolism of other drugs (e.g., cyclosporine, prednisolone, theophylline, tizanidine, and voriconazole) and increase their plasma concentrations. (Norgestrel ve etinilestradiol etiketi, İlaç etkileşimleri)

  • OfloksasinflorokinolonOrta

    This may result in a prolonged half-life for some drugs that are also metabolized by this system (e.g., cyclosporine, theophylline/methylxanthines, warfarin) when coadministered with quinolones. (Ofloksasin etiketi, İlaç etkileşimleri)

  • OksaprozinNSAİİOrta

    In order to prevent gout flares when ULORIC is initiated, concurrent prophylactic treatment with an NSAID or colchicine is recommended [see Dosage and Administration (2.4) ]. (Febuksostat etiketi, Uyarılar ve önlemler)

  • Consider use of prophylactic low-dose aspirin therapy in patients with a history of CV disease. (Febuksostat etiketi, Uyarılar ve önlemler)

  • In order to prevent gout flares when ULORIC is initiated, concurrent prophylactic treatment with an NSAID or colchicine is recommended [see Dosage and Administration (2.4) ]. (Febuksostat etiketi, Uyarılar ve önlemler)

  • PiroksikamNSAİİOrta

    In order to prevent gout flares when ULORIC is initiated, concurrent prophylactic treatment with an NSAID or colchicine is recommended [see Dosage and Administration (2.4) ]. (Febuksostat etiketi, Uyarılar ve önlemler)

  • PrimakinantimalaryalOrta

    Effects of Primaquine on the Pharmacokinetics of Other Drugs CYP1A2 Substrates Published clinical and non-clinical reports indicate primaquine inhibits CYP1A2 enzyme activity and thus may lead to increased exposure of CYP1A2 substrate drugs (e.g., duloxetine, alosetron, theophylline and tizanidine) when co-administered with Primaquine phosphate Tablets. (Primakin etiketi, İlaç etkileşimleri)

  • In order to prevent gout flares when ULORIC is initiated, concurrent prophylactic treatment with an NSAID or colchicine is recommended [see Dosage and Administration (2.4) ]. (Febuksostat etiketi, Uyarılar ve önlemler)

  • Propiltiourasilantitiroid ilaçOrta

    Theophylline: Theophylline clearance may decrease when hyperthyroid patients on a stable theophylline regimen become euthyroid; a reduced dose of theophylline may be needed. (Propiltiourasil etiketi, İlaç etkileşimleri)

  • RifapentinantibiyotikOrta

    …Clofibrate Oral Hypoglycemics Sulfonylureas (e.g., glyburide, glipizide) Hormonal Contraceptives/Progestins Ethinyl estradiol, levonorgestrel Immunosuppressants Cyclosporine, tacrolimus Methylxanthines Theophylline Narcotic analgesics Methadone Phosphodiesterase-5 (PDE-5) Inhibitors Sildenafil Thyroid preparations Levothyroxine Tricyclic antidepressants Amitriptyline,… (Rifapentin etiketi, İlaç etkileşimleri)

  • RitonavirantiretroviralOrta

    Bronchodilator: theophylline ↓ theophylline Increased dosage of theophylline may be required; therapeutic monitoring should be considered. (Ritonavir etiketi, İlaç etkileşimleri)

  • RosuvastatinstatinOrta

    Febuxostat Prevention or Management: In patients taking febuxostat, do not exceed a dosage of rosuvastatin tablets 20 mg once daily. (Rosuvastatin etiketi, İlaç etkileşimleri)

  • SalsalatNSAİİOrta

    In order to prevent gout flares when ULORIC is initiated, concurrent prophylactic treatment with an NSAID or colchicine is recommended [see Dosage and Administration (2.4) ]. (Febuksostat etiketi, Uyarılar ve önlemler)

  • SelekoksibNSAİİOrta

    In order to prevent gout flares when ULORIC is initiated, concurrent prophylactic treatment with an NSAID or colchicine is recommended [see Dosage and Administration (2.4) ]. (Febuksostat etiketi, Uyarılar ve önlemler)

  • SetirizinantihistaminikOrta

    There was a small decrease in the clearance of oral cetirizine hydrochloride caused by a 400-mg dose of theophylline; it is possible that larger theophylline doses could have a greater effect [see Clinical Pharmacology ( 12.3 )]. (Setirizin etiketi, İlaç etkileşimleri)

  • SimetidinH2 blokeriOrta

    …apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline, and metronidazole, thereby delaying elimination and increasing blood levels of these drugs. (Simetidin etiketi, İlaç etkileşimleri)

  • Drug Interactions Some studies have shown that simultaneous sucralfate administration in healthy volunteers reduced the extent of absorption (bioavailability) of single doses of the following: cimetidine, digoxin, fluoroquinolone antibiotics, ketoconazole, l-thyroxine, phenytoin, quinidine, ranitidine, tetracycline, and theophylline. (Sukralfat etiketi, İlaç etkileşimleri)

  • SulindakNSAİİOrta

    In order to prevent gout flares when ULORIC is initiated, concurrent prophylactic treatment with an NSAID or colchicine is recommended [see Dosage and Administration (2.4) ]. (Febuksostat etiketi, Uyarılar ve önlemler)

  • In order to prevent gout flares when ULORIC is initiated, concurrent prophylactic treatment with an NSAID or colchicine is recommended [see Dosage and Administration (2.4) ]. (Febuksostat etiketi, Uyarılar ve önlemler)

  • TadalafilPDE5 inhibitörüOrta

    When tadalafil was administered to subjects taking theophylline, a small augmentation (3 beats per minute) of the increase in heart rate associated with theophylline was observed. (Tadalafil etiketi, İlaç etkileşimleri)

  • Tamsulosinalfa blokerOrta

    Digoxin and Theophylline Dosage adjustments are not necessary when a tamsulosin hydrochloride capsule is administered concomitantly with digoxin or theophylline [see Clinical Pharmacology ( 12.3 )] . (Tamsulosin etiketi, İlaç etkileşimleri)

  • TeofilinmetilksantinOrta

    Therefore, use with caution when coadministering ULORIC with theophylline. (Febuksostat etiketi, İlaç etkileşimleri)

  • TerbinafinantifungalOrta

    The influence of terbinafine on the pharmacokinetics of fluconazole, cotrimoxazole (trimethoprim and sulfamethoxazole), zidovudine or theophylline was not considered to be clinically significant. (Terbinafin etiketi, İlaç etkileşimleri)

  • TeriflunomidimmünosüpresanOrta

    In patients taking AUBAGIO, exposure of drugs metabolized by CYP1A2 (e.g., alosetron, duloxetine, theophylline, tizanidine) may be reduced. (Teriflunomid etiketi, İlaç etkileşimleri)

  • TiotropiumantikolinerjikOrta

    Concomitant Respiratory Medications SPIRIVA RESPIMAT has been used concomitantly with short-acting and long-acting sympathomimetic (beta-agonists) bronchodilators, methylxanthines, oral and inhaled steroids, antihistamines, mucolytics, leukotriene modifiers, cromones, and anti-IgE treatment without increases in adverse reactions. (Tiotropium etiketi, İlaç etkileşimleri)

  • TolmetinNSAİİOrta

    In order to prevent gout flares when ULORIC is initiated, concurrent prophylactic treatment with an NSAID or colchicine is recommended [see Dosage and Administration (2.4) ]. (Febuksostat etiketi, Uyarılar ve önlemler)

  • TosilizumabimmünosüpresanOrta

    Upon initiation or discontinuation of TOFIDENCE, in patients being treated with these types of medicinal products, perform therapeutic monitoring of effect (e.g., warfarin) or drug concentration (e.g., cyclosporine or theophylline) and the individual dose of the medicinal product adjusted as needed. (Tosilizumab etiketi, İlaç etkileşimleri)

  • • Effect of Smoking Cessation on Other Drugs: Pharmacokinetics or pharmacodynamics of certain drugs (e.g., theophylline, warfarin, insulin) may be altered, necessitating dose adjustment. (Vareniklin etiketi, İlaç etkileşimleri)

  • Verapamilkalsiyum kanal blokeriOrta

    Theophylline Verapamil may inhibit the clearance and increase the plasma levels of theophylline. (Verapamil etiketi, İlaç etkileşimleri)

  • Zafirlukastlökotrien reseptör antagonistiOrta

    Coadministration of zafirlukast (20 mg/day) or placebo at steady-state with a single dose of sustained release theophylline preparation (16 mg/kg) in 16 healthy boys and girls (6 through 11 years of age) resulted in no significant differences in the pharmacokinetic parameters of theophylline. (Zafirlukast etiketi, Önlemler)

  • ZileutonCYP1A2 inhibitörüOrta

    Zileuton increases theophylline levels. (Zileuton etiketi, İlaç etkileşimleri)

Minör değinmeler (28)

  • AminofilinmetilksantinMinör

    Other xanthines such as caffeine, dyphylline, and pentoxifylline are not detected by these assays. (Aminofilin etiketi, İlaç etkileşimleri)

  • AnagrelidQT aralığını uzatan ilaçMinör

    CYP1A2 substrates: AGRYLIN demonstrates limited inhibitory activity towards CYP1A2 in vitro and may alter the exposure of concomitant CYP1A2 substrates (e.g., theophylline, fluvoxamine, ondansetron). (Anagrelid etiketi, İlaç etkileşimleri)

  • Asebutololbeta blokerMinör

    A bronchodilator, such as theophylline or a β2-stimulant, should be made available in advance with instructions concerning its use. (Asebutolol etiketi, Uyarılar)

  • Benazepril ve hidroklorotiyazidACE inhibitörüMinör

    In Vivo Drug Interaction Studies Based on drug interaction studies in healthy patients, ULORIC does not have clinically significant interactions with colchicine, naproxen, indomethacin, hydrochlorothiazide, warfarin or desipramine [see Clinical Pharmacology (12.3) ]. (Febuksostat etiketi, İlaç etkileşimleri)

  • In Vivo Drug Interaction Studies Based on drug interaction studies in healthy patients, ULORIC does not have clinically significant interactions with colchicine, naproxen, indomethacin, hydrochlorothiazide, warfarin or desipramine [see Clinical Pharmacology (12.3) ]. (Febuksostat etiketi, İlaç etkileşimleri)

  • Desipramintrisiklik antidepresanMinör

    In Vivo Drug Interaction Studies Based on drug interaction studies in healthy patients, ULORIC does not have clinically significant interactions with colchicine, naproxen, indomethacin, hydrochlorothiazide, warfarin or desipramine [see Clinical Pharmacology (12.3) ]. (Febuksostat etiketi, İlaç etkileşimleri)

  • Enalapril ve hidroklorotiyazidACE inhibitörüMinör

    In Vivo Drug Interaction Studies Based on drug interaction studies in healthy patients, ULORIC does not have clinically significant interactions with colchicine, naproxen, indomethacin, hydrochlorothiazide, warfarin or desipramine [see Clinical Pharmacology (12.3) ]. (Febuksostat etiketi, İlaç etkileşimleri)

  • Fosinopril ve hidroklorotiyazidACE inhibitörüMinör

    In Vivo Drug Interaction Studies Based on drug interaction studies in healthy patients, ULORIC does not have clinically significant interactions with colchicine, naproxen, indomethacin, hydrochlorothiazide, warfarin or desipramine [see Clinical Pharmacology (12.3) ]. (Febuksostat etiketi, İlaç etkileşimleri)

  • Hidroklorotiyazidtiyazid diüretikMinör

    In Vivo Drug Interaction Studies Based on drug interaction studies in healthy patients, ULORIC does not have clinically significant interactions with colchicine, naproxen, indomethacin, hydrochlorothiazide, warfarin or desipramine [see Clinical Pharmacology (12.3) ]. (Febuksostat etiketi, İlaç etkileşimleri)

  • İpratropiumantikolinerjikMinör

    ATROVENT HFA has been used concomitantly with other drugs, including sympathomimetic bronchodilators, methylxanthines, oral and inhaled steroids commonly used in the treatment of COPD. (İpratropium etiketi, İlaç etkileşimleri)

  • İrbesartan ve hidroklorotiyazidanjiyotensin II reseptör blokeri (ARB)Minör

    In Vivo Drug Interaction Studies Based on drug interaction studies in healthy patients, ULORIC does not have clinically significant interactions with colchicine, naproxen, indomethacin, hydrochlorothiazide, warfarin or desipramine [see Clinical Pharmacology (12.3) ]. (Febuksostat etiketi, İlaç etkileşimleri)

  • Kandesartan ve hidroklorotiyazidanjiyotensin II reseptör blokeri (ARB)Minör

    In Vivo Drug Interaction Studies Based on drug interaction studies in healthy patients, ULORIC does not have clinically significant interactions with colchicine, naproxen, indomethacin, hydrochlorothiazide, warfarin or desipramine [see Clinical Pharmacology (12.3) ]. (Febuksostat etiketi, İlaç etkileşimleri)

  • KarbamazepinantikonvülsanMinör

    Such drugs include the following: Aminophylline, c isplatin, doxorubicin, felbamate, phosphenytoin, methsuximide , phenobarbital, phenytoin, primidone, rifampin and theophylline. (Karbamazepin etiketi, İlaç etkileşimleri)

  • Kinapril ve hidroklorotiyazidACE inhibitörüMinör

    In Vivo Drug Interaction Studies Based on drug interaction studies in healthy patients, ULORIC does not have clinically significant interactions with colchicine, naproxen, indomethacin, hydrochlorothiazide, warfarin or desipramine [see Clinical Pharmacology (12.3) ]. (Febuksostat etiketi, İlaç etkileşimleri)

  • Lisinopril ve hidroklorotiyazidACE inhibitörüMinör

    In Vivo Drug Interaction Studies Based on drug interaction studies in healthy patients, ULORIC does not have clinically significant interactions with colchicine, naproxen, indomethacin, hydrochlorothiazide, warfarin or desipramine [see Clinical Pharmacology (12.3) ]. (Febuksostat etiketi, İlaç etkileşimleri)

  • Lityumserotonerjik ilaçMinör

    Acetazolamide, Urea, Xanthine Preparations, Alkalinizing Agents Clinical Impact: Concomitant use can lower serum lithium concentrations by increasing urinary lithium excretion. (Lityum etiketi, İlaç etkileşimleri)

  • Losartan ve hidroklorotiyazidanjiyotensin II reseptör blokeri (ARB)Minör

    In Vivo Drug Interaction Studies Based on drug interaction studies in healthy patients, ULORIC does not have clinically significant interactions with colchicine, naproxen, indomethacin, hydrochlorothiazide, warfarin or desipramine [see Clinical Pharmacology (12.3) ]. (Febuksostat etiketi, İlaç etkileşimleri)

  • In Vivo Drug Interaction Studies Based on drug interaction studies in healthy patients, ULORIC does not have clinically significant interactions with colchicine, naproxen, indomethacin, hydrochlorothiazide, warfarin or desipramine [see Clinical Pharmacology (12.3) ]. (Febuksostat etiketi, İlaç etkileşimleri)

  • Olmesartan ve hidroklorotiyazidanjiyotensin II reseptör blokeri (ARB)Minör

    In Vivo Drug Interaction Studies Based on drug interaction studies in healthy patients, ULORIC does not have clinically significant interactions with colchicine, naproxen, indomethacin, hydrochlorothiazide, warfarin or desipramine [see Clinical Pharmacology (12.3) ]. (Febuksostat etiketi, İlaç etkileşimleri)

  • Olmesartan, amlodipin ve hidroklorotiyazidanjiyotensin II reseptör blokeri (ARB)Minör

    In Vivo Drug Interaction Studies Based on drug interaction studies in healthy patients, ULORIC does not have clinically significant interactions with colchicine, naproxen, indomethacin, hydrochlorothiazide, warfarin or desipramine [see Clinical Pharmacology (12.3) ]. (Febuksostat etiketi, İlaç etkileşimleri)

  • Falsely high readings for theophylline have been reported in an in vitro study, using the Schack and Waxler technique, when therapeutic concentrations of theophylline and probenecid were added to human plasma. (Probenesid etiketi, İlaç etkileşimleri)

  • Ropivakainlokal anestezikMinör

    Possible interactions with drugs known to be metabolized by CYP1A2 via competitive inhibition such as theophylline and imipramine may also occur. (Ropivakain etiketi, İlaç etkileşimleri)

  • SidofovirantiviralMinör

    …Probenecid Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine). (Sidofovir etiketi, İlaç etkileşimleri)

  • Spironolakton ve hidroklorotiyazidaldosteron antagonistiMinör

    In Vivo Drug Interaction Studies Based on drug interaction studies in healthy patients, ULORIC does not have clinically significant interactions with colchicine, naproxen, indomethacin, hydrochlorothiazide, warfarin or desipramine [see Clinical Pharmacology (12.3) ]. (Febuksostat etiketi, İlaç etkileşimleri)

  • Telmisartan ve hidroklorotiyazidanjiyotensin II reseptör blokeri (ARB)Minör

    In Vivo Drug Interaction Studies Based on drug interaction studies in healthy patients, ULORIC does not have clinically significant interactions with colchicine, naproxen, indomethacin, hydrochlorothiazide, warfarin or desipramine [see Clinical Pharmacology (12.3) ]. (Febuksostat etiketi, İlaç etkileşimleri)

  • Triamteren ve hidroklorotiyazidpotasyum tutucu diüretikMinör

    In Vivo Drug Interaction Studies Based on drug interaction studies in healthy patients, ULORIC does not have clinically significant interactions with colchicine, naproxen, indomethacin, hydrochlorothiazide, warfarin or desipramine [see Clinical Pharmacology (12.3) ]. (Febuksostat etiketi, İlaç etkileşimleri)

  • Valsartan ve hidroklorotiyazidanjiyotensin II reseptör blokeri (ARB)Minör

    In Vivo Drug Interaction Studies Based on drug interaction studies in healthy patients, ULORIC does not have clinically significant interactions with colchicine, naproxen, indomethacin, hydrochlorothiazide, warfarin or desipramine [see Clinical Pharmacology (12.3) ]. (Febuksostat etiketi, İlaç etkileşimleri)

  • VarfarinantikoagülanMinör

    In Vivo Drug Interaction Studies Based on drug interaction studies in healthy patients, ULORIC does not have clinically significant interactions with colchicine, naproxen, indomethacin, hydrochlorothiazide, warfarin or desipramine [see Clinical Pharmacology (12.3) ]. (Febuksostat etiketi, İlaç etkileşimleri)

Anlamlı etkileşim olmadığı bildirilenler (10)

  • AlosetronEtkileşim yok

    The effect on CYP1A2 was explored further in a clinical interaction study with theophylline and no effect on metabolism was observed. (Alosetron etiketi, İlaç etkileşimleri)

  • DofetilidantiaritmikEtkileşim yok

    Other Drugs: In healthy volunteers, amlodipine, phenytoin, glyburide, ranitidine, omeprazole, hormone replacement therapy (a combination of conjugated estrogens and medroxyprogesterone), antacid (aluminum and magnesium hydroxides), and theophylline did not affect the pharmacokinetics of dofetilide. (Dofetilid etiketi, İlaç etkileşimleri)

  • FamsiklovirantiviralEtkileşim yok

    …Penciclovir No clinically significant alterations in penciclovir pharmacokinetics were observed following single-dose administration of 500 mg famciclovir after pretreatment with multiple doses of allopurinol, cimetidine, theophylline, zidovudine, promethazine, when given shortly after an antacid (magnesium and aluminum hydroxide), or concomitantly with emtricitabine. (Famsiklovir etiketi, İlaç etkileşimleri)

  • Finasterid5-alfa redüktaz inhibitörüEtkileşim yok

    Compounds that have been tested in man have included antipyrine, digoxin, propranolol, theophylline, and warfarin and no clinically meaningful interactions were found. (Finasterid etiketi, İlaç etkileşimleri)

  • Montelukastlökotrien reseptör antagonistiEtkileşim yok

    No dose adjustment is needed when SINGULAIR is co-administered with theophylline, prednisone, prednisolone, oral contraceptives, fexofenadine, digoxin, warfarin, gemfibrozil, itraconazole, thyroid hormones, sedative hypnotics, non-steroidal anti-inflammatory agents, benzodiazepines, decongestants, and Cytochrome P450 (CYP) enzyme inducers [see Clinical Pharmacology… (Montelukast etiketi, İlaç etkileşimleri)

  • NizatidinH2 blokeriEtkileşim yok

    Drug Interactions No interactions have been observed between nizatidine and theophylline, chlordiazepoxide, lorazepam, lidocaine, phenytoin, and warfarin. (Nizatidin etiketi, İlaç etkileşimleri)

  • OlanzapinantipsikotikEtkileşim yok

    Theophylline — Multiple doses of olanzapine did not affect the pharmacokinetics of theophylline or its metabolites. (Olanzapin etiketi, İlaç etkileşimleri)

  • Olanzapin ve fluoksetinantipsikotikEtkileşim yok

    Theophylline — Multiple doses of olanzapine did not affect the pharmacokinetics of theophylline or its metabolites. (Olanzapin ve fluoksetin etiketi, İlaç etkileşimleri)

  • Ropiniroldopamin agonistiEtkileşim yok

    Theophylline: Administration of theophylline (300 mg twice daily), a substrate of CYP1A2, did not alter the steady-state pharmacokinetics of ropinirole (2 mg 3 times daily) in 12 patients with Parkinson’s disease. (Ropinirol etiketi, İlaç etkileşimleri)

  • TiagabinantikonvülsanEtkileşim yok

    Theophylline : A single 10 mg dose of tiagabine did not affect the pharmacokinetics of theophylline at steady state. (Tiagabin etiketi, İlaç etkileşimleri)

Kullandığınız her şeyi Febuksostat ile karşılaştırın. Tüm listenizi ekleyin; her çift tek seferde kontrol edilir.

Sorgulama aracında aç

Tıbbi tavsiye değildir. Şiddet derecesi sizin koşullarınızı değil, etiketin ifadesini yansıtır. “Majör” işareti gözetim altında olağan bir uygulama olabilir, “minör” işareti ise yüksek dozlarda önem kazanabilir. Bir eczacıya danışın.